启迪药业集团股份公司关于2025年度日常关联交易预计的公告

Group 1 - The core point of the announcement is that TUS Pharmaceutical Group Co., Ltd. plans to engage in daily related transactions with its shareholder Hunan Sailoxian Management Consulting Partnership (Limited Partnership) and its related party Hunan Hengchang Pharmaceutical Group Co., Ltd., with an estimated transaction amount not exceeding 50 million yuan for the year 2025 [2][3][29] - The related transactions are deemed necessary for the company's normal business operations and are conducted under fair and reasonable principles, ensuring no harm to the interests of the company and its shareholders [2][10] - The board of directors has approved the proposal for the related transactions, which will be submitted to the shareholders' meeting for further approval, with the related shareholder Hunan Sailoxian required to abstain from voting [3][10][29] Group 2 - The expected related transactions will involve the sale of pharmaceuticals, contract manufacturing services, and research and development services between the company and Hengchang Pharmaceutical [8][9] - Hengchang Pharmaceutical is recognized as a strong player in the domestic pharmaceutical distribution sector, which will complement the company's sales network and enhance its revenue potential [9][10] - The independent directors of the company unanimously agreed that the proposed related transactions align with the company's operational needs and do not harm the interests of minority shareholders [10][23] Group 3 - The company is also planning to change its name to "Guhan Health Industry Group Co., Ltd." to better reflect its main business and enhance brand recognition among consumers and investors [12][13] - The name change requires approval from the shareholders' meeting and registration with the market supervision authority, with the final name subject to approval [13][18] - The company will continue to operate under its existing securities code, ensuring no disruption to its trading status [13][18]